Has a potential presidential order drawn a sharp response from major pharmaceutical companies?
By Oliva Fore
Copy link
Copy featured image
YES
A Trump proposal to link U.S. prescription-drug prices to prices in other countries drew immediate, public opposition from large drug companies.
The five largest drug makers have declined invitations to meet with the President A manufacturing-industry lobbying group produced an ad criticizing the proposal. The group claims the proposal would stifle drug innovation, relying on "price-setting schemes manipulated by foreign governments have no place in our economy."
Trump said he would drop the order if the industry comes up with a better idea by Aug. 24. "We may not need to implement the fourth executive order, which is a very tough order for them," he said.
This fact brief is responsive to conversations such as this one.
Sources
ABOUT THE CONTRIBUTOR
Between 2020 and 2022, under close editorial supervision, Gigafact contracted a group of freelance writers and editors to test the concepts for fact briefs and provide inputs to our software development process. We call this effort Gigafact Foundry. Over the course of these two years, Gigafact Foundry writers published over 1500 fact briefs in response to claims they found online. Their important work forms the basis of Gigafact formats and editorial guidelines, and is available to the public on Gigafact.org. Readers should be aware that while there is still a lot of relevant information to be found, not all fact briefs produced by Gigafact Foundry reflect Gigafact's current methods and standards for fact briefs. If you come across any that you feel are out of date and need to be looked at with fresh eyes, don't hesitate to contact us at support@gigafact.org.
